
    
      This trial is a single arm, open, multicenter, â…¡ period clinical research. Three cohorts were
      included, 127 subjects were enrolled (Cohort 1: about 60 subjects with surgically suitable
      muscular-invasive bladder cancer; Cohort 2: about 40 subjects with advanced Non-clear Cell
      Renal Carcinoma; Cohort 3: about 27 subjects with advanced penile carcinoma. After
      confirmation of inclusion, intravenous infusion of 10mg/kg human anti-PD-L1 monoclonal
      antibody injection (LDP) was given. The initial efficacy and safety of drugs in different
      tumor species in the cohort above will be observed.
    
  